FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896458230> ?p ?o ?g. }

• W2896458230 endingPage "1542" @default.
• W2896458230 startingPage "1530" @default.
• W2896458230 abstract "Background Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary analysis was to evaluate the prognostic value of PET–CT responses after first-line immunochemotherapy in the GALLIUM study. Methods GALLIUM is an open-label, parallel-group randomised, phase 3 trial, which recruited previously untreated patients with CD20-positive follicular lymphoma (grades 1–3a; disease stage III/IV, or stage II with largest tumour diameter ≥7 cm) who were aged 18 years or older and met the criteria for needing treatment. Eligible patients were randomly assigned in a 1:1 ratio to receive intravenous administration of obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1, then day 1 of subsequent cycles) or rituximab (375 mg/m2 on day 1 of each cycle), in six 21-day cycles with cyclophosphamide, doxorubicin, vincristine, and prednisone (known as CHOP; oral administration) followed by two 21-day cycles of antibody alone, or eight 21-day cycles cyclophosphamide, vincristine, and prednisone (known as CVP; oral administration), or six 28-day cycles with bendamustine, followed by maintenance antibody every 2 months for up to 2 years. The primary endpoint of the trial, investigator-assessed progression-free survival, has been reported previously. This secondary analysis reports PET and CT-based responses at end-of-induction therapy and explains their relation with progression-free and overall survival outcomes in patients with available scans. As per protocol, during the trial, PET scans (mandatory in the first 170 patients enrolled at sites with available PET facilities, and optional thereafter), acquired at baseline and end of induction (PET population), were assessed prospectively by investigators and an independent review committee (IRC) applying International Harmonisation Project (IHP) 2007 response criteria, and retrospectively by the IRC only applying current Lugano 2014 response criteria. IRC members (but not study investigators) were masked to treatment and clinical outcome when assessing response. The landmark analyses excluded patients who died or progressed (contrast enhanced CT-based assessment of progressive disease, or started next anti-lymphoma treatment) before or at end of induction. GALLIUM is registered at ClinicalTrials.gov, number NCT01332968. Findings 1202 patients were enrolled in GALLIUM between July 6, 2011, and Feb 4, 2014, of whom 595 were included in the PET population; 533 (IHP 2007; prospective analysis), and 508 (Lugano 2014; retrospective analysis) were analysed for progression-free survival (landmark analysis). At end of induction, 390 of 595 patients (65·5% [95% CI 61·6–69·4]) achieved PET complete response according to IHP 2007 criteria, and 450 (75·6% [95% CI 72·0–79·0]) obtained PET complete metabolic response according to Lugano 2014 criteria. With a median of 43·3 months of observation (IQR 36·2–51·8), 2·5-year progression-free survival from end of induction was 87·8% (95% CI 83·9–90·8) in PET complete responders and 72·0% (63·1–79·0) in non-complete responders according to IRC-assessed IHP 2007 criteria (hazard ratio [HR] 0·4, 95% CI 0·3–0·6, p<0·0001). According to Lugano 2014 criteria, 2·5-year progression-free survival in complete metabolic responders was 87·4% (95% CI 83·7–90·2) and in non-complete metabolic responders was 54·9% (40·5–67·3; HR 0·2, 95% CI 0·1–0·3, p<0·0001). Interpretation Our results suggest that PET is a better imaging modality than contrast-enhanced CT for response assessment after first-line immunochemotherapy in patients with follicular lymphoma. PET assessment according to Lugano 2014 response criteria provides a platform for investigation of response-adapted therapeutic approaches. Additional supportive data are welcomed. Funding F Hoffmann-La Roche." @default.
• W2896458230 created "2018-10-26" @default.
• W2896458230 creator A5000432967 @default.
• W2896458230 creator A5000733045 @default.
• W2896458230 creator A5000982586 @default.
• W2896458230 creator A5001394341 @default.
• W2896458230 creator A5001659585 @default.
• W2896458230 creator A5001923702 @default.
• W2896458230 creator A5002135260 @default.
• W2896458230 creator A5003273516 @default.
• W2896458230 creator A5003662791 @default.
• W2896458230 creator A5003887338 @default.
• W2896458230 creator A5004568132 @default.
• W2896458230 creator A5005029408 @default.
• W2896458230 creator A5005798452 @default.
• W2896458230 creator A5006107813 @default.
• W2896458230 creator A5007500042 @default.
• W2896458230 creator A5007640080 @default.
• W2896458230 creator A5008613923 @default.
• W2896458230 creator A5009667571 @default.
• W2896458230 creator A5010574507 @default.
• W2896458230 creator A5010750526 @default.
• W2896458230 creator A5010845006 @default.
• W2896458230 creator A5011091303 @default.
• W2896458230 creator A5011371393 @default.
• W2896458230 creator A5011827144 @default.
• W2896458230 creator A5011863718 @default.
• W2896458230 creator A5012157148 @default.
• W2896458230 creator A5012590429 @default.
• W2896458230 creator A5012926122 @default.
• W2896458230 creator A5013112899 @default.
• W2896458230 creator A5013551807 @default.
• W2896458230 creator A5013630484 @default.
• W2896458230 creator A5013949384 @default.
• W2896458230 creator A5014639728 @default.
• W2896458230 creator A5014979722 @default.
• W2896458230 creator A5015509689 @default.
• W2896458230 creator A5015650333 @default.
• W2896458230 creator A5016541702 @default.
• W2896458230 creator A5016790466 @default.
• W2896458230 creator A5017050164 @default.
• W2896458230 creator A5017171769 @default.
• W2896458230 creator A5017739829 @default.
• W2896458230 creator A5017740329 @default.
• W2896458230 creator A5018352650 @default.
• W2896458230 creator A5018546005 @default.
• W2896458230 creator A5018968800 @default.
• W2896458230 creator A5019857338 @default.
• W2896458230 creator A5019885844 @default.
• W2896458230 creator A5020021596 @default.
• W2896458230 creator A5020125932 @default.
• W2896458230 creator A5020200414 @default.
• W2896458230 creator A5020554225 @default.
• W2896458230 creator A5020586738 @default.
• W2896458230 creator A5021837954 @default.
• W2896458230 creator A5021965002 @default.
• W2896458230 creator A5022277766 @default.
• W2896458230 creator A5022970809 @default.
• W2896458230 creator A5024161871 @default.
• W2896458230 creator A5024620381 @default.
• W2896458230 creator A5025565506 @default.
• W2896458230 creator A5026306458 @default.
• W2896458230 creator A5027006412 @default.
• W2896458230 creator A5027118202 @default.
• W2896458230 creator A5027645258 @default.
• W2896458230 creator A5027986359 @default.
• W2896458230 creator A5028457340 @default.
• W2896458230 creator A5028464891 @default.
• W2896458230 creator A5028510513 @default.
• W2896458230 creator A5029448872 @default.
• W2896458230 creator A5029450431 @default.
• W2896458230 creator A5031973195 @default.
• W2896458230 creator A5031977714 @default.
• W2896458230 creator A5032061719 @default.
• W2896458230 creator A5033045722 @default.
• W2896458230 creator A5033935778 @default.
• W2896458230 creator A5034043513 @default.
• W2896458230 creator A5034517642 @default.
• W2896458230 creator A5035398527 @default.
• W2896458230 creator A5035562927 @default.
• W2896458230 creator A5036000764 @default.
• W2896458230 creator A5036324396 @default.
• W2896458230 creator A5036936763 @default.
• W2896458230 creator A5037105339 @default.
• W2896458230 creator A5037546722 @default.
• W2896458230 creator A5038128263 @default.
• W2896458230 creator A5038191750 @default.
• W2896458230 creator A5038637530 @default.
• W2896458230 creator A5038685198 @default.
• W2896458230 creator A5038714255 @default.
• W2896458230 creator A5038946138 @default.
• W2896458230 creator A5039257959 @default.
• W2896458230 creator A5039588117 @default.
• W2896458230 creator A5039853793 @default.
• W2896458230 creator A5040156395 @default.
• W2896458230 creator A5040642952 @default.
• W2896458230 creator A5041249662 @default.
• W2896458230 creator A5042527927 @default.

• next